Cartherics Pty Ltd
Website: http://cartherics.com
Member Contact: Professor Alan Trounson
Position: Chief Executive Officer
Industry: Biotech & Pharmaceuticals
Company Profile:
Cartherics is a private biotechnology company focused on allogeneic stem cell immune therapies for cancer. The company has developed autologous CAR-T therapies for T cell lymphoma and relapsed ovarian cancer that will be in FIH clinical trials 2022-23 at the Peter Mac Cancer Institute. The allogeneic iPSC derived CAR-iNK cell product is expected to be in clinical trials by 2024 for ovarian cancer with a pipeline of developments that include therapy for TAG72+ adenocarcinomas, CAR-iT cells and other targets.
Cartherics is presently sited at expanded lab and office facilities at 12 Ferntree Place, Notting Hill VIC. The company has around 30 staff and key consultants and is expecting to significantly expand in the next five years. The company is engaged in its own research and has affiliations with the Australian Regenerative Medicine Institute (ARMI) at Monash University, the CCRM, Peter Mac Cancer Institute, ToolGen (Korea), RheinCell (Germany), Monash and Epworth Medical Centres and other institutes and companies world-wide.
Cartherics has PhD Hons students enrolled through Monash University and is actively developing new immune therapeutic approaches to treat cancer and serious infections. The team actively encourages biotechnology developments in closely associated areas of regenerative medicine and the education of scientists in the academic industry interphase.
